NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Its the MOA that should be important to them and not that the drug is approved in another indication or not. On the other hand, if the licensing was happening to commercialize in GBM then waiting for approval this late in the game makes sense. Otherwise, it’s just a waste of time.

You see so many licensing deals where the drug is still in phase 2 trial or has encouraging data from phase 1/2 and then get licensing agreement from big pharma with large upfront payment, subsequent additional milestone payments and then percentage royalties on sales.